The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
-
Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224
Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Mayo Clinic,
Fernando Fervenza, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic, Rochester, MN
Nabeel Aslam, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic
2029-03-02